Figure 2. . Frequencies of participant responses when asked to select up to five most-important factors when deciding overall preference between treatments for (A) adult patients and (B) caregivers of pediatric patients.

Participants were asked to select up to five factors that were most important to them when deciding their overall preference between prior eculizumab treatment and ravulizumab.

aHUS: Atypical hemolytic uremic syndrome.